Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer
A synthetic saponin conjugate with TLR agonists in liposomes or emulsions addresses the limitations of natural saponins, providing a safer and scalable adjuvant system for enhanced immune response.
WO2025180443A1 Publication Date: 2025-09-04IMMUNADD INC
6 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/079539
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-29
- Filing Date
- 2025-02-27
- Publication Date
- 2025-09-04
AI Technical Summary
Technical Problem
Existing saponin-based adjuvants face challenges with dose-limiting toxicity, inadequate stability, unclear molecular mechanism of action, and scalability issues, limiting their clinical success and production.
Method used
Development of a synthetic saponin conjugate (Synsap) combined with a TLR agonist, formulated in liposomes or emulsions, to enhance immune response and address the limitations of natural saponins.
Benefits of technology
The synthetic saponin conjugate provides a safer, more stable, and scalable adjuvant system with defined structure-activity relationships, inducing both humoral and cellular immunity, and overcoming production and scalability challenges.
✦ Generated by Eureka AI based on patent content.
Abstract
An adjuvant composition comprises: a saponin conjugate represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof; and a TLR agonist, wherein the formula (I) is shown as follows.
Need to check novelty before this filing date? Find Prior Art